HWN Suggests

Quadruple Screening in the Age of Cell-Free DNA: What are We Losing?

The development of the quad screen helped to identify pregnancies at the highest risk of body wall defects and fetal aneuploidy, allowing for a reduction in the amount of invasive diagnostic testing. NIPT has since emerged as a more sensitive and specific means of identifying possible fetal aneuploidy. As we move more towards this means of screening, it is important to recognize the potential gaps that this testing alone leaves. The largest of these gaps is the detection of NTDs and abdominal wall defects, making routine second trimester US a critical component of the prenatal testing algorithm. Additionally, there is ongoing investigational research that might suggest a further benefit of serum…

read full article

Featured

 Quad screen vs. NIPT: Understanding your prenatal screening options

The quad screen estimates your baby’s risk by measuring the levels of four specific hormones and proteins in your blood. These biomarkers (AFP, hCG, estriol, and inhibin A) typically fall within a certain range during pregnancy. Still, as factors like your age, weight, and ethnicity can influence these levels, they’re also factored into the analysis. The results are considered normal if your hormone levels are within the expected range for your baby’s gestational age. If they’re too high or too low, this may indicate an increased risk of a genetic condition. In contrast, NIPT doesn’t measure hormone levels — it examines cfDNA. The test analyzes your baby’s chromosomes for any extra, duplicate, or missing copies. If it detects an imbalance, it indicates a higher risk of a chromosomal condition.

Articles of Interest

Advantages of the Quadruple Screen over noninvasive prenatal testing

While NIPT may be the most accurate screening for certain aneuploidies, the American College of Obstetricians and Gynecologists and the Society of Maternal‐Fetal Medicine caution that its use is solely for fetal aneuploidy and that NIPT should not be part of routine laboratory assessment, but instead should be an informed patient choice for women at high risk of fetal aneuploidy 5. In patients who are at risk of placental‐based pregnancy complications the integrated screen may be a better option for assessment of fetal chromosomal abnormalities, placental function, and fetal risks associated with placental dysfunction.

Correlation of pregnancy outcome with quadruple screening test at second trimester

The risk of having an APO such as pre-eclampsia (p=0.008), fetal growth restriction (p=0.028) and premature rupture of membrane (p=0.040) increased significantly in patients with abnormal markers.

New Standard for Prenatal Screening – The Quad Test

The Quad Test is replacing the Triple Test as the standard prenatal screening procedure... This is because the Quad Test is able to detect more cases of Down syndrome than earlier screening methods while decreasing the false positive rate.

Performance of Serum Quad Test in Screening for Fetal Down Syndrome in a Large-Scale Unselected Population in a Developing Country

Quad test is highly effective in service settings and suitable for developing countries and the effectiveness is even higher when based on ethnicity-specific reference model.

Quad test for fetal aneuploidy screening as a predictor of small-for-gestational age fetuses: a population-based study

The quad test for aneuploidy screening could also be used as a predictor of SGA, without extra-effort and extra-cost. Small for gestational age (SGA), usually defined as fetuses with birthweight of less than the 10th percentile of the gestational age, is one of the common conditions of high-risk pregnancy, leading to poor pregnancy outcomes, such as perinatal morbidity and mortality as well as abnormal neurodevelopment.

Quadruple test parameters in art pregnancies

In conclusion quadruple test results of ART pregnancies gave higher than expected screen positive results and serum levels of all four biomarkers were increased. When we consider that most of these women achieved their pregnancy after a long-standing infertility and treatment, avoiding unnecessary amniocentesis might be more important for this subgroup of patients. Nowadays screening with cell-free fetal DNA in maternal serum seems to be a better option in this subgroup of pregnants.

Triple or Quad Screening for Birth Defects

The triple screening measures the amounts of three substances in a pregnant woman's blood: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and estriol (uE3). When a test for the hormone inhibin A is added, it's called a quad screening. These tests are also called the maternal serum triple or quad test, the expanded AFP test, the AFP plus test, or the multiple marker screening test.

What Is a Quad Screen Test for Pregnancy: Everything You Need to Know

The quad screen test, also known as the quadruple marker test, is a prenatal screening tool typically performed during the second trimester of pregnancy. It is designed to assess the risk of certain fetal conditions, including neural tube defects and chromosomal abnormalities such as Down syndrome. The test measures the levels of four specific substances in the mother's blood: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), estriol, and inhibin-A.

What is the AFP PLUS® Quad Test?

It can tell you whether you have a high likelihood of having a baby with either a neural tube defect, Down syndrome, or trisomy 18. Ultimately, about one in 12 patients will have a "screen positive" AFP PLUS test result. If your test result is screen positive, it does not necessarily mean that your baby has one of these disorders, but it does mean that your doctor will suggest some additional testing.

What Tests Are Done in a Quadruple Marker for Women in Pregnancy?

A blood test known as a quad screening or quadruple marker is used to find any chromosomal abnormalities or birth problems in an unborn child during the second trimester of pregnancy. The quadruple marker test can assist in determining the fetus's likelihood of developing specific diseases, such as Down's syndrome, Edward's syndrome, and neural tube abnormalities. It is usually conducted between weeks 14 and 22 of pregnancy, and the existence of multiple fetuses might also be detected using this test.

Resources

American Pregnancy Association

The quad screen is a maternal blood screening test which is similar to the Triple Screen Test (also know as AFP Plus and the Multiple Marker Screening). However, the quad screen looks for not only the three specific substances evaluated in those tests (AFP, hCG, and Estriol) but also a fourth substance known as Inhibin-A. The screen is essentially the same as the screening tests that look for only three substances, except the likelihood of identifying pregnancies at risk for Down Syndrome is higher through the evaluation of Inhibin-A levels.

Genomics Education Programme

The quadruple screening test is offered to pregnant women in the second trimester (from 14 to 20 weeks’ gestation). It assesses the chance of a pregnancy being affected by trisomy 21 (Down syndrome). It does not screen for trisomy 18 (Edwards syndrome) or trisomy 13 (Patau syndrome). Quadruple screening is usually offered when combined first-trimester screening cannot be offered